Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy
Gergely Imre,Bertalan Takács,Erik Czipa,Andrea Bakné Drubi,Gábor Jaksa,Dóra Latinovics,Andrea Nagy,Réka Karkas,Liza Hudoba,Bálint Márk Vásárhelyi,Gabriella Pankotai-Bodó,András Blastyák,Zoltán Hegedűs,Péter Germán,Balázs Bálint,Khaldoon Sadiq Ahmed Abdullah,Anna Georgina Kopasz,Anita Kovács,László G Nagy,Farkas Sükösd,Lajos Pintér,Thomas Rülicke,Endre Barta,István Nagy,Lajos Haracska,Lajos Mátés
DOI: https://doi.org/10.1016/j.omtm.2023.03.003
2023-03-14
Abstract:DNA transposon-based gene delivery vectors represent a promising new branch of randomly integrating vector development for gene therapy. For the side-by-side evaluation of the piggyBac and Sleeping Beauty systems-the only DNA transposons currently employed in clinical trials-during therapeutic intervention, we treated the mouse model of tyrosinemia type I with liver-targeted gene delivery using both transposon vectors. For genome-wide mapping of transposon insertion sites we developed a new next-generation sequencing procedure called streptavidin-based enrichment sequencing, which allowed us to identify approximately one million integration sites for both systems. We revealed that a high proportion of piggyBac integrations are clustered in hot regions and found that they are frequently recurring at the same genomic positions among treated animals, indicating that the genome-wide distribution of Sleeping Beauty-generated integrations is closer to random. We also revealed that the piggyBac transposase protein exhibits prolonged activity, which predicts the risk of oncogenesis by generating chromosomal double-strand breaks. Safety concerns associated with prolonged transpositional activity draw attention to the importance of squeezing the active state of the transposase enzymes into a narrower time window.